| Ytd | -38.08% | |
| 1y | 0.76% |
| Open | 4.04 | Prev Close | 4.04 | Low | 4.00 | High | 4.07 | Mkt Cap | 401.20M |
| Vol | 123.70K | Avg Vol | 1.85M | EPS | -0.61 | P/E | -6.62 | Forward P/E | -5.87 |
| Beta | 1.45 | Short Ratio | 6.37 | Inst. Own | 55.98% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 4.21 | 200-d Avg | 4.80 | 1yr Est | 10.83 |
AQST News
WARREN, N.J., July 07, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquesti
Aquestive Therapeutics (AQST) was a big mover last session on higher-than-average trading volume. Th
Aquestive Therapeutics, Inc. (AQST) Q1 2026 Earnings Call Transcript
Aquestive Therapeutics NASDAQ: AQST said it remains on track to resubmit its new drug application fo
U.S. stocks rose, with Dow Jones up 300 points. STAA shares surged after better-than-expected result
While the top- and bottom-line numbers for Aquestive Therapeutics (AQST) give a sense of how the bus
Aquestive Therapeutics (AQST) came out with a quarterly loss of $0.07 per share versus the Zacks Con
Aquestive Therapeutics (NASDAQ:AQST) affirms FY2026 sales outlook from $46.000 million-$50.000 milli
Aquestive Therapeutics (NASDAQ:AQST) reported quarterly losses of $(0.07) per share which beat the a
WARREN, N.J., May 13, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquesti
WARREN, N. J. , May 12, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aques
WARREN, N.J., May 06, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquesti
NEW YORK--(BUSINESS WIRE)---- $AQST #AQST--Faruqi & Faruqi, LLP, a leading national securities law f
NEW YORK, May 04, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recogniz
New York, New York--(Newsfile Corp. - May 4, 2026) - WHY: Rosen Law Firm, a global investor rights l
Aquestive Therapeutics (AQST) doesn't possess the right combination of the two key ingredients for a
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suff
NEW YORK, May 3, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, remind
New York, New York--(Newsfile Corp. - May 3, 2026) - Bronstein, Gewirtz and Grossman, LLC, a nationa
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suff
NEW YORK, May 02, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, r
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suff
Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmac
Aquestive Therapeutics (NASDAQ:AQST) sees FY2026 sales of $46.000 million-$50.000 million vs $49.888
Aquestive Therapeutics (NASDAQ:AQST) reported quarterly losses of $(0.15) per share which missed the
Aquestive received an FDA rejection for its allergy film due to safety and use issues. The company p
Deficiencies limited to packaging and administration Company believes it can rapidly resolve defi
Benzinga examined the prospects for many investors' favorite stocks over the last week — here
ARS Pharmaceuticals Inc. stock rose Friday as FDA identified deficiencies in rival Aquestive's a
Aquestive Therapeutics shares fall after the FDA flags deficiencies in its Anaphylm allergy drug app
Announces receipt of FDA letter stating it has identified deficiencies that preclude labeling discus
Announces receipt of FDA letter stating it has identified deficiencies that preclude labeling discus
U.S. stocks were higher, with the Dow Jones index gaining more than 200 points on Friday. Shares